Tag: Immunotherapy
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
Five-year PFS was 28.5 percent and overall survival was 40.3 percent; 40.2 percent of patients did not meet ZUMA-1 eligibility criteria
Adverse Events Up With Immune Checkpoint Blockade Added to Periop Cancer Therapy
Increase seen in incidence of grade 3 to 4 treatment-related adverse events, adverse events leading to treatment discontinuation
Sublingual Immunotherapy Safe, Effective for Treating Toddlers’ Peanut Allergy
Improved outcomes seen with younger age at initiation
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
Anti-PD-L1 agent induces sustained responses seen in about one-third of patients with advanced alveolar soft part sarcoma
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
Progression-free survival and overall survival prolonged with zolbetuximab plus CAPOX versus placebo plus CAPOX
Some Immunosuppressed Do Not Have Anti-Spike Antibodies After COVID-19 Vaccination
IgG anti-spike antibodies undetectable in ~20 percent with immunosuppression who had received three or more COVID-19 vaccines
Most Immunosuppressive Drugs Not Linked to Risk for Cancer
No associations seen for TNF inhibitor, antimetabolite, calcineurin inhibitor, or alkylating agent classes with cancer
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
Significant improvement seen in progression-free survival for combination of nivolumab and ipilimumab
Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
Worse OS seen in association with visceral metastases, ECOG performance status ≥1, higher neutrophil/lymphocyte ratio
